STOCK PICK OF 2022?

BUILT FOR GROWTH, DRIVING VALUE

One of the leading Canadian B2B post-harvest solutions providers, Ayurcann is one of the most innovative publicly traded companies in the adult and medical-use markets.

CSE:AYUR is focused on becoming the partner of choice for leading Canadian brands and  yielding continuous returns for investors.

Is this your opportunity to join the $10.1 billion 2.0 market? 

+1,149%

Increase In Net Revenue

$7.6mm for the fiscal year ending June 30, 2021

+440%

Increase In Operating income

$2.1mm for the fiscal year ending June 30, 2021

$2.1 Mil

Adjusted EBIDTA In 2021

Representing gross margins of approximately 60%

Get the latest investor news

MARKET OPPORTUNITY

A Rapidly Growing 2.0 Market Segment

As the 2.0 market matures, it moves away from vertical integration.

The 2.0 market is growing at an exponential rate – what’s an emerging market of today will transition into a mature industry lead by companies that specialize and develop competitive advantages in the value chain.

Ayurcann is well-positioned to capitalize on the 2.0 market evolution

Canadian 2.0 Market*

Canadian 2.0 Segment Sales Growth**

THE VALUE CHAIN

Ayurcann's Competitive Advantage

 Leading 2.0 Product Manufacturer

 Very low OPEX = Massive Operating Leverage

 High Gross Margins

 High-Margin Branded Product Offerings

 EBITDA and Cash Flow Positive

 Debt Free

Ayurcann is a leading extraction company in Canada, focused on providing and creating custom processes and pharma-grade products for the adult and medical use markets.
home-icon-1.png

Competitive

home-icon-2.png

CERTIFIED

home-icon-3.png

INNOVATIVE

Get the latest investor news

TOP SERVICES + TOP PRODUCTS + COMPETITIVE YET PROFITABLE PRICING =

Key Success Factors

Services to Partners & Brands

Efficient technology + infrastructure providing top quality, timely service at competitive pricing

Proven traction with over 20 clients and counting

Medicinal Line of Products

XPLOR brand serves medicinal B2B market, 6 SKUs at launch

Ayurcann Marketplace now offering direct sales to registered patients 

Operational & Financial Excellence

Over $7.6 million in revenue booked in Fiscal year ending June 30, 2021 

Over $2 million in adjusted EBITDA

Low OPEX relative to competitors

OFFERINGS

Competitive Product Lines

Extraction-2.jpg

Extraction & Refinement

 Processed over 16,000 kgs of biomass, to date

 Ethanol extraction specialty

 Low to high volume production capabilities

 Fast and flexible production

Bottle-2.jpg

Bulk Oil Sales

 Secured monthly biomass supply

 Over 300 kg monthly distillate inventory

 Inventory-to-supply leading license producers, supporting edibles, topicals, and inhalables

 Quality supply of crude, distillate, and isolates

homepage-who-we-are.jpg

White Label Manufacturing

 In-house developed IP formulation

 20+ product offering SKUs

 Custom extracts and formulations

 Branding and packaging capabilities

Get the latest investor news

© 2021 Ayurcann Inc. All Rights Reserved.

NO INVESTMENT ADVICE

This website is published on behalf of Ayurcann Holdings Inc. This site provides general information and discussions about health and financial subjects. The information in this site, or any linked materials, is not intended to replace medical or financial advice, nor is the information a substitute for professional expertise, treatment, or financial recommendations. If you or any person has a medical or financial concern, you should consult with your health care provider or financial advisor.
post harvest solutions

Subscribe to our newsletter to stay up-to-date with Ayurcann.